Author

D. Sergienko

h-index 3 View on Semantic Scholar

We have 3 of 58 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Efficacy and safety of switching within one international non-proprietary name (elexacaftor/tezacaftor/ivacaftor) in children with cystic fibrosis: clinical experience of transition from Trikafta to Trilexa

Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane regulator gene and is accompanied by chronic damage to the respiratory and gastrointestinal systems. Triple therapy with elexacaftor, tezacaftor, and ivacaftor significantly improves lung function and nutritional status. However, the high cos...

D. Sergienko, O. Golubtsova, E. A. Enina · ASTRAKHAN MEDICAL JOURNAL · 0 citations

Open access Jul 2026

Efficacy and safety of pathogenetic therapy for cystic fibrosis in children in the Chechen Republic: Use of a generic CFTR modulator and experience of switching within a same international non-proprietary name

The use of both the original drug and generic Trilexa in children with CF is associated with clinical improvements in key efficacy indicators and a favorable safety profile.

M. R. Shakhgireeva, A. Ibisheva, A. B. Khildikharoeva et al. · Meditsinskiy sovet = Medical... · 0 citations

Open access Jul 2026

Regional features of the cystic fibrosis pediatric population structure and pathogenetic therapy coverage with CFTR-modulators in the Southern Federal District of the Russian Federation

The available data show a signficant progress in the availability of pathogen-oriented therapy in the SFD, but there remain genetic, age-related, and institutional barriers limiting full patient coverage with highly effective CFTR-modulators.

V. Brisin, A. E. Kidakoeva, S. Trishina et al. · Meditsinskiy sovet = Medical... · 0 citations